Siemens enters field of molecular services for oncology

Siemens Healthcare acquires NEO New Oncology

Siemens Healthineers has expanded its diagnostics portfolio with the acquisition of NEO New Oncology, Cologne, Germany. The company’s cancer genome diagnostic platform NEO1 will support pathologists and oncologists with comprehensive molecular information to help select targeted cancer therapies. NEO New Oncology is developing molecular profiling assays based on NGS (Next Generation Sequencing), both for tissue specimens and body liquids. This includes NEO liquid, a liquid biopsy test for the analysis of genomic profiles of solid tumours from a simple blood sample. NEO New Oncology’s high quality third generation hybrid capture technology allows for the analysis of circulating tumour DNA with high accuracy.

The acquisition of NEO New Oncology provides Siemens Healthineers an entry point into NGS-based genomic testing and expands its capabilities in precision medicine and companion diagnostics. Furthermore, Siemens Healthineers establishes a business prospect in the field of molecular services, with the plan to provide testing and enablement services to physicians, hospitals and laboratories, including access to the latest medical knowledge and technologies.